Эозинофилия может быть признаком ряда патологий pravda.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pravda.ru Daily Mail and Mail on Sunday newspapers.
Note that some links may require registration or subscription.
On the heels of its recently released data in teens ages 12-15, Pfizer and BioNTech said they applied to the FDA to expand emergency use authorization for their COVID-19 vaccine to include that age group.
Reuters)
Johnson & Johnson s COVID-19 vaccine is in hot water, with the European Medicines Agency announcing an investigation into post-vaccination blood clots. Closer to home, vaccine sites in North Carolina, Colorado and Georgia temporarily shut down administration of the vaccine due to adverse reactions. (
Bloomberg, CBS News)
As of Monday at 8:00 a.m. EST, the unofficial U.S. COVID-19 toll is 31,198,232 cases and 562,066 deaths, an increase of almost 492,000 cases and almost 7,100 deaths from a week ago jumping about 10% and 25%, respectively, from the previous week s totals.
Spoiler alert: The vaccines work!
ZDoggMD talks about how the new coronavirus vaccines are remarkably safe and effective and why it s about time that the CDC stated the obvious. He also touches on Facebook censorship.
Following is a rough transcript of his remarks (Note: errors are possible):
ZDoggMD: What s up, everybody? Welcome to the ZDoggMD show. The CDC has basically come out today and said what we ve all been thinking for the past few weeks meaning the people that I ve had on my show what I ve been saying publicly, which is if you re vaccinated, vaccines are the endpoint of this pandemic. It s the way we get out of this.
email article
The peanut-powder oral treatment Palforzia became the first FDA-approved immunotherapy for food allergy in late January 2020. The peanut (Arachis Hypogaea) allergen powder-dnfp is designed to desensitize peanut allergies in children and adolescents, and prevent potentially life-threatening reactions.
Within 6 weeks of its approval for use in children, age 4-17 years, most of the U.S. shut down due to the pandemic, and it was widely agreed that the timing of the immunotherapy s arrival on the U.S. market was less than optimal.
A little over a year later, it is still unclear to what degree physicians, parents, and patients will embrace peanut allergy immunotherapy (IT), along with IT for other food allergies when they become available. The topic was front and center at the American American Academy of Allergy, Asthma & Immunotherapy (AAAAI) virtual meeting, with newly reported data from pivotal Palforzia trials, and data on the investigational epicutaneous IT tre